Loader

Pathways

PathWhiz ID Pathway Meta Data

PW146600

Pw146600 View Pathway
drug action

Alclofenac Drug Metabolism Action Pathway

Homo sapiens

PW292657

Pw292657 View Pathway
metabolic

Alcaligin Siderophore Repression (alcABC Operon activation)

Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251)
The alcABC operon, is involved in the production of alcaligin, a siderophore that helps bacteria acquire iron from the host environment. The operon is made up of 3 genes - alcA, alcB, and alcC. AlcA encodes a protein believed to be involved in the initial steps of alcaligin biosynthesis. alcB encodes a protein also involved in the biosynthesis of alcaligin. AlcC encodes a protein that is similar to IucC, another enzyme involved in siderophore biosynthesis. The operon is regulated by iron availability. It is repressed in the presence of iron. The transcriptional regulator protein Fur (ferric uptake regulator) binds to the promoter region of the operon when iron is abundant, inhibiting transcription, ensuring that the operon is only expressed when iron is scarce.

PW175963

Pw175963 View Pathway
metabolic

Alcaftadine Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Alcaftadine are predicted with biotransformer.

PW176782

Pw176782 View Pathway
drug action

Alcaftadine H1-Antihistamine Immune Response Action Pathway

Homo sapiens
Alcaftadine is a H1 histamine receptor antagonist for ophthalmic use to prevent itching associated with allergic conjunctivitis. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176690

Pw176690 View Pathway
drug action

Alcaftadine H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Alcaftadine is a H1 histamine receptor antagonist for ophthalmic use to prevent itching associated with allergic conjunctivitis. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Alcaftadine inhibits the H1 histamine receptor on blood vessel endothelial cells. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin. Calcium bound calmodulin is required for the activation of the calmodulin-binding domain of nitric oxide synthase. The inhibition of nitric oxide synthesis prevents the activation of myosin light chain phosphatase. This causes an accumulation of myosin light chain-phosphate which causes the muscle to contract and the blood vessel to constrict, decreasing the swelling and fluid leakage from the blood vessels caused by allergens.

PW063838

Pw063838 View Pathway
drug action

Alcaftadine H1-Antihistamine Action

Homo sapiens
Alcaftadine is a second-generation piperidine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176597

Pw176597 View Pathway
drug action

Alcaftadine H1 Antihistamine Smooth Muscle Relaxation Action Pathway

Homo sapiens
Alcaftadine is a H1 histamine receptor antagonist for ophthalmic use to prevent itching associated with allergic conjunctivitis. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Alcaftadine also inhibits the H1 histamine receptor on bronchiole smooth muscle myocytes. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin.Calcium bound calmodulin is required for the activation of myosin light chain kinase. This prevents the phosphorylation of myosin light chain 3, causing an accumulation of myosin light chain 3. This causes muscle relaxation, opening up the bronchioles in the lungs, making breathing easier.

PW145775

Pw145775 View Pathway
drug action

Alcaftadine Drug Metabolism Action Pathway

Homo sapiens

PW144637

Pw144637 View Pathway
drug action

Albendazole Drug Metabolism Action Pathway

Homo sapiens

PW127418

Pw127418 View Pathway
drug action

Albendazole Action Pathway

Homo sapiens
Albendazole is a broad-spectrum benzimidazole anthelmintic used to treat parenchymal neurocysticercosis and other helminth infections. Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by diminishing its energy production, ultimately leading to immobilization and death of the parasite. It works by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. As cytoplasmic microtubules are critical in promoting glucose uptake in larval and adult stages of the susceptible parasites, the glycogen stores of the parasites are depleted. Cellular glucose dissipates which results in decreased production and dissipation of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes also result in decreased production of adenosine triphosphate (ATP),